LIVED EXPERIENCE with SEVERE AORTIC VALVE STENOSIS (AORTIC STENOSIS) From collapsing in Thailand to meeting technicians who hand-stitched heart valve in Singapore
With
Geoffrey Lewis, Age 75
Diagnosed with severe aortic stenosis, following collapse
Rebecca Pickles,
daughter of Geoffrey Lewis
LIVED EXPERIENCE SEGMENT
Filmed in Sydney | September 2026
A Batemans Bay grandfather who dismissed months of breathlessness and fatigue as “just getting older” is now preparing to travel to Singapore to meet the technicians who hand-stitched the heart valve that helped save his life.
In April 2026, retired logistics courier, Geoff Lewis, 75, collapsed in front of his daughter and grandchildren while on holiday in Thailand, after months of symptoms he had ignored. The collapse would lead to a diagnosis of severe aortic stenosis and urgent treatment back home.
Aortic stenosis is a narrowing of the heart valve which makes the heart work harder to pump blood around the body.(1)
When left untreated, severe symptomatic aortic stenosis is associated with poor outcomes, with more than half of those affected potentially dying within two years. (2)
The disease most commonly affects those aged 65 years and over, and its symptoms are often mistaken for the normal signs of ageing, (3) such as gradual reduction in exercise capacity, shortness of breath, fatigue (tiredness) and tightness, or pain in the chest. (4)
An estimated 100,000 Australians are living with severe aortic stenosis, with a further 10,000 new cases developing each year.2 The disease is increasingly treatable,6 and can often be identified through a routine heart examination, including listening for a heart murmur with a stethoscope.(5)
Treatment depends on the severity of the condition and an individual’s circumstances. Options may include monitoring or valve replacement, including surgical approaches or minimally invasive procedures such as transcatheter aortic valve implantation (TAVI).
Citations:
- Strange, G., et al., Uncovering the treatable burden of severe aortic stenosis in Australia: current and future projections within an ageing population. BMC Health Services Research, 2021. 21(1): p. 790.
- Otto, C.M., Timing of aortic valve surgery. Heart (British Cardiac Society), 2000. 84(2): p. 211-218.
- Hope For Hearts. Symptoms of Aortic Stenosis. [July 2026]; Available from: https://hopeforhearts.com.au/aortic-stenosis/symptoms/.
- Victor Chang Cardio Research Institute. Aortic Stenosis. [July 2026]; Available from: https://www.victorchang.edu.au/aortic-stenosis.
- The Baker Heart and Diabetes Institute. Our hidden ageing: Time to listen to the heart. 2021; Available from: https://www.baker.edu.au/impact/advocacy/valve-disease.
Source: Adapted from media release, VIVA! Communications Pty Ltd – a GHMC Company August 2026. Supplied footage: Edwards Lifesciences (Singapore)
-
The role of genomic screening in transforming public health
Dr Jane Tiller is a lawyer, genetic counsellor and public health researcher. She is Ethical, Legal & Social Adviser in Public Health Genomics at Monash University, and a National Health and Medical Research Council Investigator Grant holder. Jane is passionate about the use of genomics to prevent disease, and in delivering equitable access to preventive genetic information at the population level. She is co-lead of DNA Screen, a world-first study piloting the offer of preventive DNA screening to the Australian adult population. DNA Screen has tested over 10,000 young people for genetic high risk of medically actionable conditions such as cancer and heart disease, finding about 2% of participants had genetic high risk. Jane is leading efforts to secure Commonwealth Government funding to expand the DNA Screen program, with the eventual goal of the development of a public health population screening program for disease prevention based on high genetic risk.
-
Australian Teletrial Program reaches significant milestones in trials and participants
Launched in 2022, the Australian Teletrial Program is an initiative designed to improve access to clinical trials for people living in regional and remote areas of Australia. It uses telemedicine and digital technologies to enable patients to participate in clinical trials without needing to travel long distances to major metropolitan centres, which can often be a barrier to participation for those in rural and isolated locations.
Recently Australian Health Journal met with Kaye Hewson, Director, Australian Teletrials Program, who spoke about the program’s recent achievements.
-
Pharmacist Prescribing Model gets further support from state health
A full scope pharmacist prescriber model allows pharmacists to independently prescribe medicines within their professional competence, without requiring prior doctor authorisation. It extends pharmacists’ role beyond dispensing to include assessment, diagnosis of minor and chronic conditions, initiation and modification of therapy, and ongoing patient monitoring. This model integrates pharmacists into primary care teams, aiming to improve timely access to treatment, reduce pressure on general practitioners, and enhance continuity of care. Pharmacists use their clinical knowledge, patient records, and collaborative pathways to ensure safe prescribing. The model emphasises training, regulation, and accountability to maintain high standards of patient safety.
